Abstract: Objective   To observe the shortterm and longterm curative effect of pemetrexed combined with carboplatin on advanced nonsmall cell lung cancer (NSCLC). Methods   A total of 92 NSCLC patients treated in the hospital from June 2015 to September 2017 were selected and divided into observation group and control group by random, 46 cases in each group. Control group was given gemcitabine combined with carboplatin, while observation group received carboplatin combined with pemetrexed.The total response rate (RR) of treatment, scores of Lung Cancer Symptom Scale (LCSS) before and after treatment, 1year survival rate, mortality and recurrence rate, and the occurrence of toxic and side effects during treatment were compared between two groups. Results  RR in observation group was higher than that in control group (P<0.05). After treatment, LCSS scores in observation group were higher than those in control group (P<0.05). The 1year survival rate in observation group was higher than that in control group, while the mortality and recurrence rates were lower than those in control group (P<0.05).  The incidences of bone marrow suppression and gastrointestinal reactions in observation group were lower than those in control group (P<0.05). Conclusion  The application of pemetrexed combined with carboplatin in the treatment of advanced NSCLC has a high efficiency, which can increase the 1year survival rate, improve the quality of life, and reduce the incidence of toxic and side effects.

Key words: carcinoma, , nonsmallcell lung； pemetrexed, carboplatin, survival rate, drug toxicity